Cangrelor free acid (AR-C69931; ARC-69931MX; Kengreal, CANREAL; Kengrexal), an adenylic acid analog, is a selective P2Y12 inhibitor that was approved in June 2015 as an antiplatelet drug for intravenous application. As a modified ATP analog, Cangrelor is stable to enzymatic degradation and does not require metabolic reaction to become an active metabolite, which is different from the prodrug clopidogrel (Plavix). This allows cangrelor's immediate effect after infusion, and the therapeutic effects can be maintained with continuous infusion.

纯度：≥98%

CAS：163706-06-7